On the stock market since 2022, it operates in the world of health and science. It has 158 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 16% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 44% below its peak. The market has trimmed its expectations for the company.
The company sells $4.7B a year; the problem isn’t sales — it’s costs running above that number.
There is $1.0B in the vault; even if every debt were paid off, $472M would remain.
A loss of $253M against $4.7B in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
The sales tempo runs behind the sector. Council score: 4/10.
On our five-subject report card, PCNEF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PCNEF has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.